Paclitaxel poliglumex vs. docetaxel for the second-line treatment of non-small cell lung cancer (NSCLC): the STELLAR 2 phase III study

被引：0
|
作者：
不详
机构：
来源：
EJC SUPPLEMENTS | 2005年 / 3卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：14 / 14
页数：1
相关论文
共 50 条
  • [41] Phase II study of weekly paclitaxel as second-line therapy in patients with advanced non-small cell lung cancer
    Ceresoli, GL
    Gregorc, V
    Cordio, S
    Bencardino, KB
    Schipani, S
    Cozzarini, C
    Bordonaro, R
    Villa, E
    LUNG CANCER, 2004, 44 (02) : 231 - 239
  • [42] Second-line chemotherapy for advanced non-small cell lung cancer (NSCLC) with weekly versus three-weekly docetaxel: Results of a randomized phase III study.
    Schuette, W
    Nagel, S
    Serke, M
    Lautenschlaeger, C
    Hans, K
    Lorenz, C
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 625S - 625S
  • [43] Phase II study of cabazitaxel as second-line therapy in stage IV non-small cell lung cancer (NSCLC).
    Das, Devika
    Robert, Francisco
    Bordoni, Rodolfo
    Grant, Stefan C.
    Saleh, Mansoor N.
    Reddy, Vishnu
    Jerome, Mary
    Miley, Debi
    Singh, Karen P.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [44] Weekly docetaxel as second-line chemotherapy in advanced non-small cell lung cancer: Phase II trial
    Serke, M
    Schoenfeld, N
    Loddenkemper, R
    ANTICANCER RESEARCH, 2004, 24 (2C) : 1211 - 1216
  • [45] Second line treatment of non-small cell lung cancer with paclitaxel and gemcitabine
    Kakolyris, S
    Kourousis, C
    Androulakis, N
    Dimopoulos, MA
    Papadakis, E
    Tzannes, S
    Kotsakis, T
    Vardakis, N
    Merambeliotakis, N
    Kalbakis, C
    Xatzidaki, D
    Georgoulias, V
    EUROPEAN JOURNAL OF CANCER, 1997, 33 : 1049 - 1049
  • [46] Updated report of a phase III study of induction therapy with gemcitabine plus carboplatin (GC) followed by either delayed vs. immediate second-line therapy with docetaxel (D) in advanced non-small cell lung cancer (NSCLC).
    Fidias, P.
    Dakhil, S. R.
    Lyss, A. P.
    Loesch, D. M.
    Waterhouse, D.
    Cunneen, J.
    Ye, Z.
    Tai, F.
    Obasaju, C. K.
    Schiller, J. H.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 372S - 372S
  • [47] Paclitaxel poligiumex vs. gemcitabine or vinorelbine for the treatment of performance status (PS) 2 patients with chernotherapy-naive advanced non-small cell lung cancer (NSCLC): the STELLAR 4 phase III study
    O'Brien, M.
    Oldham, F.
    EJC SUPPLEMENTS, 2005, 3 (02): : 324 - 324
  • [48] Prognostic score for second-line chemotherapy of advanced non-small cell lung cancer (NSCLC): External validation in a phase III trial comparing vinflunine with docetaxel.
    Krzakowski, M. J.
    Di Maio, M.
    Perraud, K.
    Kowalski, D. M.
    Gridelli, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [49] Effect of estrogen on outcome in two randomized phase III studies of paclitaxel poliglumex (PPX) in advanced non-small cell lung cancer (NSCLC)
    O'Byrne, K.
    Singer, J. W.
    Oldham, F. B.
    Ross, H.
    EJC SUPPLEMENTS, 2006, 4 (12): : 194 - 195
  • [50] Efficacy of racotumomab or nimotuzumab vs docetaxel as second-line therapy for advanced non-small cell lung cancer patients
    Hernandez, M.
    Neninger, E.
    Santiesteban, E.
    Camacho, K.
    Hernandez, N.
    Amador, R.
    Acosta, S.
    Gonzalez, Y.
    Jimenez, Y.
    Corella, M.
    Ortiz, R. A.
    Bello, L.
    Calana, A.
    Pichs, G.
    Cala, M.
    Flores, Y.
    Viada, C.
    Robaina, M.
    Crombet, T.
    ANNALS OF ONCOLOGY, 2018, 29 : 415 - 415
12345